Russia’s Stem Cell Institute said on Wednesday it plans to raise up to 165 million roubles ($5.53 million) in what will be the country’s first initial public offering since the financial crisis erupted last year.
If the IPO goes ahead as expected, Stem Cell Institute would have an implied market capitalisation of 825 million roubles.
Stem Cell Institute set an indicative price range of the IPO at between 9 and 11 roubles per ordinary share and the offering will comprise approximately 15 million ordinary shares.
International Stem Cell Corporation announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called “transducible transcription factors” or “TTFs.” TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products.
In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells. In addition, the
Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company’s Phase IIb clinical trial treating acute ischemic stroke.
Dr. Alan Moore, President and CEO, commented as follows:
“We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future
Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells (…)
The relatively small payment reflects that “it’s really early for cell therapy and there’s more research to be done,” said Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, a unit created by the company about 18 months ago to develop treatments based on stem cells (…)
Incoming search terms:stemgenex complaints, stemgenex reviews, stemgenex cost, Athersys Fraud, is stemgenex legit, stemgenex review, stemedix complaints against, complaints against